Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Duodenal Recellularization Via Electroporation Therapy as an Early Treatment for Type 2 Diabetes Mellitus (DREAM-1 Study)

NCT07376486 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT07376486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07376486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Duodenal Recellularization Via Electroporation Therapy as an Early Treatment for Type 2 Diabetes Mellitus (DREAM-1 Study)
Lead sponsor
Chinese University of Hong Kong
Phase
Not applicable
Overall status
Recruiting
Start date
September 1, 2026
Completion date
August 30, 2032
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabete mellitus, t2 diabetes and fatty liver disease (non-alcoholic origin)